NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Takeda
Sotio Biotech Inc.
Alaunos Therapeutics
BioNTech SE
Baylor College of Medicine
Incyte Corporation
Bristol-Myers Squibb
Emory University
Palleon Pharmaceuticals, Inc.
University of Chicago
NGM Biopharmaceuticals, Inc
Precision Biologics, Inc
Intensity Therapeutics, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ImmunityBio, Inc.
NantCell, Inc.
BioNTech SE
ImmunityBio, Inc.
NantCell, Inc.
NantCell, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
Peptomyc S.L.
Georgetown University
Galera Therapeutics, Inc.
Processa Pharmaceuticals
University of Texas Southwestern Medical Center
Barbara Ann Karmanos Cancer Institute
MedImmune LLC
Genmab
Revolution Medicines, Inc.
Barbara Ann Karmanos Cancer Institute
Kyntra Bio
Mereo BioPharma
Corcept Therapeutics
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Gilead Sciences
Novartis
Bristol-Myers Squibb
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Mayo Clinic
M.D. Anderson Cancer Center
Targovax ASA
University of Wisconsin, Madison
Celgene